View ValuationHubei DinglongLtd 향후 성장Future 기준 점검 5/6Hubei DinglongLtd (는) 각각 연간 30% 및 24.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 30% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 19.2% 로 예상됩니다.핵심 정보30.0%이익 성장률29.97%EPS 성장률Chemicals 이익 성장30.6%매출 성장률24.2%향후 자기자본이익률19.24%애널리스트 커버리지Low마지막 업데이트20 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Independent Director Xinping Xia was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Mar 31+ 1 more updateHubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026Hubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026, at 14:30 China Standard Time. Location: 6F, Executive Building 1, No. 1, Dongjinghe Road, Wuhan Economic and Technological Development Zone, Hubei China공시 • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026공시 • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025공시 • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025공시 • Jun 13Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million on June 10, 2025. A cash consideration of CNY 240 million will be paid by Hubei Dinglong CO.,Ltd. As part of consideration, CNY 240 million is paid towards common equity of Hubei Dinghui Microelectronic Materials Co., Ltd. Upon completion, Hubei Dinglong CO.,Ltd. will own 99.35% stake in Hubei Dinghui Microelectronic Materials Co., Ltd. For the period ending December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total revenue of CNY 717.23 million. As of December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total assets of CNY 1.35 billion and total common equity of CNY 963.08 million. The transaction has been approved by the board of Hubei Dinglong CO.,Ltd.공시 • May 22Hubei Dinglong Co.,Ltd. Approves Cash Dividend for the Year 2024Hubei Dinglong CO.,Ltd. held its Annual General Meeting of 2024 on 20 May 2025, during which the following proposal(s) was/were approved: 2024 profit distribution plan of Cash dividend/10 shares (tax included): CNY 1.00000000.공시 • Apr 29Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025, at 15:00 China Standard Time.공시 • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공시 • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Buy Or Sell Opportunity • Nov 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CN¥29.00. The fair value is estimated to be CN¥24.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 100% in the next 2 years.Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥23.85, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.39 per share.공시 • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024Reported Earnings • Aug 20Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.063 in 2Q 2023). Revenue: CN¥810.8m (up 32% from 2Q 2023). Net income: CN¥136.3m (up 123% from 2Q 2023). Profit margin: 17% (up from 10.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Jun 29Hubei Dinglong CO.,Ltd. to Report First Half, 2024 Results on Aug 20, 2024Hubei Dinglong CO.,Ltd. announced that they will report first half, 2024 results on Aug 20, 2024Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.086 (vs CN¥0.037 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.086 (up from CN¥0.037 in 1Q 2023). Revenue: CN¥708.0m (up 30% from 1Q 2023). Net income: CN¥81.6m (up 135% from 1Q 2023). Profit margin: 12% (up from 6.4% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.공시 • Apr 10Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024, at 15:00 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei ChinaReported Earnings • Apr 10Full year 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.24 (down from CN¥0.42 in FY 2022). Revenue: CN¥2.67b (down 2.0% from FY 2022). Net income: CN¥222.0m (down 43% from FY 2022). Profit margin: 8.3% (down from 14% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.공시 • Mar 30Hubei Dinglong CO.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024Buy Or Sell Opportunity • Mar 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CN¥21.51. The fair value is estimated to be CN¥27.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 73%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 116% in the next 2 years.공시 • Mar 16Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million on March 13, 2024. Transaction was financed by Hubei Dinglong's own funds. Transaction has already been approved by Wuhan Rouxian Technology Co., Ltd's board of director's.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥20.42, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 13x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.66 per share.공시 • Feb 07Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 200 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price not more than CNY 30 per share. The purpose of the program is to use the repurchased shares for ESOP or equity incentives. The program is valid for a period of 3 months.공시 • Dec 30Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2023 results on Apr 10, 2024Reported Earnings • Oct 26Third quarter 2023 earnings released: EPS: CN¥0.093 (vs CN¥0.10 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.093 (down from CN¥0.10 in 3Q 2022). Revenue: CN¥713.2m (up 11% from 3Q 2022). Net income: CN¥80.4m (down 20% from 3Q 2022). Profit margin: 11% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.공시 • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023Reported Earnings • Aug 19Second quarter 2023 earnings released: EPS: CN¥0.063 (vs CN¥0.13 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.063 (down from CN¥0.13 in 2Q 2022). Revenue: CN¥612.7m (down 18% from 2Q 2022). Net income: CN¥61.1m (down 50% from 2Q 2022). Profit margin: 10.0% (down from 17% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.공시 • Jul 01Hubei Dinglong CO.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023Hubei Dinglong CO.,Ltd. announced that they will report first half, 2023 results on Aug 19, 2023공시 • Jun 09Hubei Dinglong Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 16, 2023Hubei Dinglong CO.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.50000000 on A shares for the year 2022. Record date is June 15, 2023. Ex-date is May June 16, 2023. Payment date is June 16, 2023.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥29.90, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 162% over the past three years.Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.23 in FY 2021)Full year 2022 results: EPS: CN¥0.42 (up from CN¥0.23 in FY 2021). Revenue: CN¥2.72b (up 16% from FY 2021). Net income: CN¥390.0m (up 83% from FY 2021). Profit margin: 14% (up from 9.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.062 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.062 in 3Q 2021). Revenue: CN¥642.9m (up 16% from 3Q 2021). Net income: CN¥100.3m (up 70% from 3Q 2021). Profit margin: 16% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.Valuation Update With 7 Day Price Move • Oct 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥19.19, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 105% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.39 per share.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥26.51, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 154% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.08 per share.Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.058 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.14 (up from CN¥0.058 in 2Q 2021). Revenue: CN¥742.8m (up 29% from 2Q 2021). Net income: CN¥123.1m (up 129% from 2Q 2021). Profit margin: 17% (up from 9.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.04 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.076 (up from CN¥0.04 in 1Q 2021). Revenue: CN¥569.7m (up 9.6% from 1Q 2021). Net income: CN¥71.4m (up 90% from 1Q 2021). Profit margin: 13% (up from 7.2% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. 3 independent directors (8 non-independent directors). Independent Director Xiao Ji was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥0.23 (vs CN¥0.17 loss in FY 2020)Full year 2021 results: EPS: CN¥0.23 (up from CN¥0.17 loss in FY 2020). Revenue: CN¥2.36b (up 30% from FY 2020). Net income: CN¥213.5m (up CN¥373.3m from FY 2020). Profit margin: 9.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 51% growth forecast for the industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥554.9m (up 25% from 3Q 2020). Net income: CN¥59.2m (up 45% from 3Q 2020). Profit margin: 11% (up from 9.2% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 159 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥576.4m (up 9.2% from 2Q 2020). Net income: CN¥53.9m (down 71% from 2Q 2020). Profit margin: 9.3% (down from 35% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 10Full year 2020 earnings released: CN¥0.17 loss per share (vs CN¥0.036 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CN¥1.82b (up 58% from FY 2019). Net loss: CN¥159.8m (down CN¥193.9m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Jan 21New 90-day high: CN¥23.44The company is up 52% from its price of CN¥15.38 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.87 per share.Is New 90 Day High Low • Jan 05New 90-day high: CN¥19.30The company is up 23% from its price of CN¥15.70 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.94 per share.Is New 90 Day High Low • Dec 17New 90-day high: CN¥17.45The company is up 5.0% from its price of CN¥16.61 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.97 per share.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥97.7m, down 59% from the prior year. Total revenue was CN¥1.61b over the last 12 months, up 40% from the prior year.Is New 90 Day High Low • Oct 23New 90-day low: CN¥15.38The company is down 15% from its price of CN¥18.06 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.06 per share.Is New 90 Day High Low • Sep 28New 90-day low: CN¥15.59The company is down 6.0% from its price of CN¥16.60 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.03 per share.이익 및 매출 성장 예측XSEC:300054 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20287,6291,9871,8122,362212/31/20275,9581,3871,2281,647412/31/20264,5141,0487531,53313/31/20263,8568305161,201N/A12/31/20253,6607203811,157N/A9/30/20253,610664128990N/A6/30/20253,550614103926N/A3/31/20253,454580102904N/A12/31/20243,33852160828N/A9/30/20243,220422-71780N/A6/30/20243,027344-303677N/A3/31/20242,828269-436619N/A12/31/20232,667222-494534N/A9/30/20232,639272-537440N/A6/30/20232,568291-393489N/A3/31/20232,698353-176572N/A12/31/20222,721390-113563N/A9/30/20222,660358-57525N/A6/30/20222,572317-153331N/A3/31/20222,406247-327139N/A12/31/20212,356214-3693N/A9/30/20212,214-249-34257N/A6/30/20212,102-268-24261N/A3/31/20212,054-13761292N/A12/31/20201,817-160181389N/A9/30/20201,60698-137116N/A6/30/20201,40193-52155N/A3/31/20201,161-55197N/A12/31/20191,14934N/A198N/A9/30/20191,146240N/A308N/A6/30/20191,224302N/A338N/A3/31/20191,292298N/A327N/A12/31/20181,338293N/A298N/A9/30/20181,443339N/A296N/A6/30/20181,528312N/A287N/A3/31/20181,626311N/A289N/A12/31/20171,700336N/A346N/A9/30/20171,632294N/A278N/A6/30/20171,624296N/A280N/A3/31/20171,457272N/A286N/A12/31/20161,306240N/A296N/A9/30/20161,215218N/A251N/A6/30/20161,083186N/A208N/A3/31/20161,051163N/A144N/A12/31/20151,050159N/A117N/A9/30/20151,007155N/A160N/A6/30/2015980145N/A129N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 300054 의 연간 예상 수익 증가율(30%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 300054 의 연간 수익(30%)이 CN 시장(27%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 300054 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 300054 의 수익(연간 24.2%)이 CN 시장(연간 16%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 300054 의 수익(연간 24.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 300054의 자본 수익률은 3년 후 19.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 03:32종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hubei Dinglong CO.,Ltd.는 9명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullChina International Capital Corporation LimitedYilin HouChina International Capital Corporation LimitedAda WangChina Stock Investment Research Co. Ltd. (GZ500..com)6명의 분석가 더 보기
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Independent Director Xinping Xia was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Mar 31+ 1 more updateHubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026Hubei Dinglong CO.,Ltd., Annual General Meeting, Apr 24, 2026, at 14:30 China Standard Time. Location: 6F, Executive Building 1, No. 1, Dongjinghe Road, Wuhan Economic and Technological Development Zone, Hubei China
공시 • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026
공시 • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
공시 • Jul 02Hubei Dinglong CO.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025Hubei Dinglong CO.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
공시 • Jun 13Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire Hubei Dinghui Microelectronic Materials Co., Ltd. from CCB Trust Co., Ltd. for CNY 240 million on June 10, 2025. A cash consideration of CNY 240 million will be paid by Hubei Dinglong CO.,Ltd. As part of consideration, CNY 240 million is paid towards common equity of Hubei Dinghui Microelectronic Materials Co., Ltd. Upon completion, Hubei Dinglong CO.,Ltd. will own 99.35% stake in Hubei Dinghui Microelectronic Materials Co., Ltd. For the period ending December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total revenue of CNY 717.23 million. As of December 31, 2024, Hubei Dinghui Microelectronic Materials Co., Ltd. reported total assets of CNY 1.35 billion and total common equity of CNY 963.08 million. The transaction has been approved by the board of Hubei Dinglong CO.,Ltd.
공시 • May 22Hubei Dinglong Co.,Ltd. Approves Cash Dividend for the Year 2024Hubei Dinglong CO.,Ltd. held its Annual General Meeting of 2024 on 20 May 2025, during which the following proposal(s) was/were approved: 2024 profit distribution plan of Cash dividend/10 shares (tax included): CNY 1.00000000.
공시 • Apr 29Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025Hubei Dinglong CO.,Ltd., Annual General Meeting, May 20, 2025, at 15:00 China Standard Time.
공시 • Mar 31Hubei Dinglong CO.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공시 • Dec 31Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Buy Or Sell Opportunity • Nov 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CN¥29.00. The fair value is estimated to be CN¥24.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 100% in the next 2 years.
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.093 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.093 in 3Q 2023). Revenue: CN¥906.9m (up 27% from 3Q 2023). Net income: CN¥158.5m (up 97% from 3Q 2023). Profit margin: 18% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥23.85, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.39 per share.
공시 • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
Reported Earnings • Aug 20Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.063 in 2Q 2023). Revenue: CN¥810.8m (up 32% from 2Q 2023). Net income: CN¥136.3m (up 123% from 2Q 2023). Profit margin: 17% (up from 10.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Jun 29Hubei Dinglong CO.,Ltd. to Report First Half, 2024 Results on Aug 20, 2024Hubei Dinglong CO.,Ltd. announced that they will report first half, 2024 results on Aug 20, 2024
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.086 (vs CN¥0.037 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.086 (up from CN¥0.037 in 1Q 2023). Revenue: CN¥708.0m (up 30% from 1Q 2023). Net income: CN¥81.6m (up 135% from 1Q 2023). Profit margin: 12% (up from 6.4% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
공시 • Apr 10Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024Hubei Dinglong CO.,Ltd., Annual General Meeting, May 14, 2024, at 15:00 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei China
Reported Earnings • Apr 10Full year 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.24 (down from CN¥0.42 in FY 2022). Revenue: CN¥2.67b (down 2.0% from FY 2022). Net income: CN¥222.0m (down 43% from FY 2022). Profit margin: 8.3% (down from 14% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
공시 • Mar 30Hubei Dinglong CO.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024Hubei Dinglong CO.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
Buy Or Sell Opportunity • Mar 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CN¥21.51. The fair value is estimated to be CN¥27.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 73%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 116% in the next 2 years.
공시 • Mar 16Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million.Hubei Dinglong CO.,Ltd. (SZSE:300054) agreed to acquire 6.83% stake in Wuhan Rouxian Technology Co., Ltd. from Qushui Dinglong Taihao Enterprise Management Co., Ltd. managed by Wuhan Paradise Silicon Valley Technology Innovation Asset Management Co., Ltd. for CNY 31.9 million on March 13, 2024. Transaction was financed by Hubei Dinglong's own funds. Transaction has already been approved by Wuhan Rouxian Technology Co., Ltd's board of director's.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥20.42, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 13x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.66 per share.
공시 • Feb 07Hubei Dinglong CO.,Ltd. (SZSE:300054) announces an Equity Buyback for CNY 200 million worth of its shares.Hubei Dinglong CO.,Ltd. (SZSE:300054) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price not more than CNY 30 per share. The purpose of the program is to use the repurchased shares for ESOP or equity incentives. The program is valid for a period of 3 months.
공시 • Dec 30Hubei Dinglong CO.,Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024Hubei Dinglong CO.,Ltd. announced that they will report fiscal year 2023 results on Apr 10, 2024
Reported Earnings • Oct 26Third quarter 2023 earnings released: EPS: CN¥0.093 (vs CN¥0.10 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.093 (down from CN¥0.10 in 3Q 2022). Revenue: CN¥713.2m (up 11% from 3Q 2022). Net income: CN¥80.4m (down 20% from 3Q 2022). Profit margin: 11% (down from 16% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
공시 • Sep 30Hubei Dinglong CO.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023Hubei Dinglong CO.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023
Reported Earnings • Aug 19Second quarter 2023 earnings released: EPS: CN¥0.063 (vs CN¥0.13 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.063 (down from CN¥0.13 in 2Q 2022). Revenue: CN¥612.7m (down 18% from 2Q 2022). Net income: CN¥61.1m (down 50% from 2Q 2022). Profit margin: 10.0% (down from 17% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
공시 • Jul 01Hubei Dinglong CO.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023Hubei Dinglong CO.,Ltd. announced that they will report first half, 2023 results on Aug 19, 2023
공시 • Jun 09Hubei Dinglong Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 16, 2023Hubei Dinglong CO.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.50000000 on A shares for the year 2022. Record date is June 15, 2023. Ex-date is May June 16, 2023. Payment date is June 16, 2023.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥29.90, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 162% over the past three years.
Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.23 in FY 2021)Full year 2022 results: EPS: CN¥0.42 (up from CN¥0.23 in FY 2021). Revenue: CN¥2.72b (up 16% from FY 2021). Net income: CN¥390.0m (up 83% from FY 2021). Profit margin: 14% (up from 9.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.062 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.062 in 3Q 2021). Revenue: CN¥642.9m (up 16% from 3Q 2021). Net income: CN¥100.3m (up 70% from 3Q 2021). Profit margin: 16% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥19.19, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 105% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.39 per share.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥26.51, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 154% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.08 per share.
Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.058 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.14 (up from CN¥0.058 in 2Q 2021). Revenue: CN¥742.8m (up 29% from 2Q 2021). Net income: CN¥123.1m (up 129% from 2Q 2021). Profit margin: 17% (up from 9.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
Board Change • Jun 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Minguang Su was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.04 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.076 (up from CN¥0.04 in 1Q 2021). Revenue: CN¥569.7m (up 9.6% from 1Q 2021). Net income: CN¥71.4m (up 90% from 1Q 2021). Profit margin: 13% (up from 7.2% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 29%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. 3 independent directors (8 non-independent directors). Independent Director Xiao Ji was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥0.23 (vs CN¥0.17 loss in FY 2020)Full year 2021 results: EPS: CN¥0.23 (up from CN¥0.17 loss in FY 2020). Revenue: CN¥2.36b (up 30% from FY 2020). Net income: CN¥213.5m (up CN¥373.3m from FY 2020). Profit margin: 9.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 51% growth forecast for the industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥554.9m (up 25% from 3Q 2020). Net income: CN¥59.2m (up 45% from 3Q 2020). Profit margin: 11% (up from 9.2% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 159 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.18 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥576.4m (up 9.2% from 2Q 2020). Net income: CN¥53.9m (down 71% from 2Q 2020). Profit margin: 9.3% (down from 35% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 10Full year 2020 earnings released: CN¥0.17 loss per share (vs CN¥0.036 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CN¥1.82b (up 58% from FY 2019). Net loss: CN¥159.8m (down CN¥193.9m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Jan 21New 90-day high: CN¥23.44The company is up 52% from its price of CN¥15.38 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.87 per share.
Is New 90 Day High Low • Jan 05New 90-day high: CN¥19.30The company is up 23% from its price of CN¥15.70 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.94 per share.
Is New 90 Day High Low • Dec 17New 90-day high: CN¥17.45The company is up 5.0% from its price of CN¥16.61 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥12.97 per share.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥97.7m, down 59% from the prior year. Total revenue was CN¥1.61b over the last 12 months, up 40% from the prior year.
Is New 90 Day High Low • Oct 23New 90-day low: CN¥15.38The company is down 15% from its price of CN¥18.06 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.06 per share.
Is New 90 Day High Low • Sep 28New 90-day low: CN¥15.59The company is down 6.0% from its price of CN¥16.60 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.03 per share.